Eliem Therapeutics Shifts From Neurology With New Found Focus On Autoimmune Diseases With Tenet Medicines Deal
Eliem Therapeutics Shifts From Neurology With New Found Focus On Autoimmune Diseases With Tenet Medicines Deal
Eliem Therapeutics Inc (NASDAQ:ELYM) has agreed to acquire Tenet Medicines Inc., a development-stage private biotechnology company.
Eliem Therapeutics Inc.（納斯達克股票代碼：ELYM）已同意收購處於開發階段的私營生物技術公司Tenet Medicines Inc.。
The combined company plans to focus on advancing TNT119, an anti-CD19 antibody designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy.
合併後的公司計劃專注於開發 TNT119，這是一種抗CD19抗體，專爲包括系統性紅斑狼瘡、免疫性血小板減少和膜性腎病在內的多種自身免疫性疾病而設計。
In June 2023, Eliem Therapeutics completed a review of its business, including the status of its programs, resources, and capabilities. The company has decided to halt further development of its Kv7 program and comprehensively explore strategic alternatives.
2023年6月，Eliem Therapeutics完成了對其業務的審查，包括其計劃、資源和能力的狀況。該公司已決定停止其Kv7計劃的進一步開發，並全面探索戰略替代方案。
Also, Eliem entered a securities purchase agreement for a $120 million private placement. Eliem has agreed to sell 31.2 million shares at $3.84 per share.
此外，Eliem還簽訂了1.2億美元的私募證券購買協議。Eliem已同意以每股3.84美元的價格出售3,120萬股股票。
The private placement is expected to close concurrently with the closing of the acquisition anticipated in mid-2024.
私募預計將與預計於2024年中期完成的收購同時完成。
The combined company's total cash and cash equivalents are expected to be approximately $210 million.
合併後的公司的現金和現金等價物總額預計約爲2.1億美元。
Eliem expects this will be sufficient to fund the combined company's planned operations into 2027 and to enable the potential attainment of key clinical and development milestones for TNT119.
埃利姆預計，這將足以爲合併後的公司2027年的計劃運營提供資金，並有可能實現 TNT119 的關鍵臨床和研發里程碑。
"The Eliem board of directors has conducted a thorough review of strategic alternatives, and we believe the transaction we are announcing today with Tenet presents a compelling opportunity for our stockholders," said Andrew Levin, Executive Chairman of Eliem. "We believe TNT119 represents a promising clinical asset across multiple autoimmune diseases targeting markets where there is a need for improved treatment options."
Eliem執行主席安德魯·萊文表示：“Eliem董事會已經對戰略選擇進行了全面的審查，我們認爲我們今天宣佈的與Tenet的交易爲我們的股東提供了一個絕佳的機會。”“我們認爲，在多種自身免疫性疾病中，TNT119 是一項前景光明的臨床資產，目標市場需要改善治療方案。”
Pre-acquisition Tenet equity holders are expected to own approximately 15% of the combined company, and pre-acquisition Eliem equity holders are expected to own approximately 85%.
收購前的Tenet股權持有人預計將擁有合併後公司約15％的股份，收購前的Eliem股權持有人預計將擁有約85％的股份。
Price Action: ELYM shares are up 56.2% at $4.17 on the last check Thursday.
價格走勢：在週四的最後一次支票中，ELYM股價上漲56.2％，至4.17美元。
譯文內容由第三人軟體翻譯。